Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ivospemin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at AACR
    Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at AACR

    30 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/01/30/2819984/37414/en/Acceptance-of-Ivospemin-SBP-101-Abstract-for-Poster-Presentation-at-American-Association-for-Cancer-Research-AACR.html

    GLOBENEWSWIRE
    30 Jan 2024
    Share Share
    Panbela Announces First Patient Enrolled in ASPIRE Trial Studying Ivospemin
    Panbela Announces First Patient Enrolled in ASPIRE Trial Studying Ivospemin

    07 Mar 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/03/07/2621993/37414/en/Panbela-Announces-First-Patient-Enrolled-in-South-Korea-for-ASPIRE-Trial-Studying-Ivospemin-SBP-101-in-Combination-with-Gemcitabine-and-Nab-Paclitaxel-in-Patients-with-Metastatic-P.html

    GLOBENEWSWIRE
    07 Mar 2023
    Share Share
    Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin with Gemcitabine and Nab-Paclitaxel
    Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin with Gemcitabine and Nab-Paclitaxel

    19 Jan 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/01/19/2591871/37414/en/Panbela-Announces-Adoption-of-Commission-Implementing-Decision-from-the-EMA-for-the-Orphan-Designation-of-Ivospemin-SBP-101-in-Combination-with-Gemcitabine-and-Nab-Paclitaxel-in-Pa.html

    GLOBENEWSWIRE
    19 Jan 2023
    Share Share
    Panbela Receives EMA Opinion on Orphan Designation for Ivospemin
    Panbela Receives EMA Opinion on Orphan Designation for Ivospemin

    14 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/12/14/2573721/37414/en/Panbela-Receives-Positive-EMA-Opinion-on-Orphan-Designation-for-Ivospemin-SBP-101-in-Combination-with-Gemcitabine-and-Nab-Paclitaxel-in-Patients-with-Metastatic-Pancreatic-Ductal-A.html

    GLOBENEWSWIRE
    14 Dec 2022
    Share Share